Papers

The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study

BMJ 2004; 329 doi: https://doi.org/10.1136/bmj.38167.684444.3A (Published 26 August 2004) Cite this as: BMJ 2004;329:484
  1. Paolo Prandoni, associate professor (paoloprandoni{at}tin.it)1,
  2. Enrico Bernardi, medical doctor1,
  3. Antonio Marchiori, medical doctor1,
  4. Anthonie W A Lensing, medical doctor2,
  5. Martin H Prins, professor3,
  6. Sabina Villalta, medical doctor1,
  7. Paola Bagatella, medical doctor1,
  8. Donatella Sartor, medical doctor1,
  9. Andrea Piccioli, medical doctor1,
  10. Paolo Simioni, assistant professor1,
  11. Antonio Pagnan, professor1,
  12. Antonio Girolami, professor1
  1. 1 Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University Hospital of Padua, Via Ospedale Civile 105, 35128 Padua, Italy
  2. 2 Center for Vascular Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands
  3. 3 Department of Clinical Epidemiology and Technology Assessment, University of Maastricht, PO Box 5800, 6202 AZ Maastricht, Netherlands
  1. Correspondence to: P Prandoni
  • Accepted 24 May 2004

Introduction

The diagnosis and treatment of deep vein thrombosis of the arm are documented extensively.1 2 The long term clinical course of the condition is, however, poorly defined.

Participants, methods, and results

Fifty three consecutive patients with a first, symptomatic deep vein thrombosis of the arm, confirmed by ultrasonography or venography—including six cases related to catheter insertion—were treated with high dose heparin, followed by at least three months of warfarin (targeted international normalised ratio 2.0-3.0) (table).

Characteristics of the study patients (n=53). Values are numbers (percentages) of patients unless otherwise indicated

View this table:

Follow up visits were scheduled after three and six months, and then every six months up to five years. At each visit, patients underwent a clinical evaluation, for which we used a standardised scale previously validated in patients with venous thrombosis in the leg,3 4 and an ultrasound assessment of the affected venous segments. Each of five symptoms (heaviness, pain, itching, physical limitation, and paraesthesia) and six signs (pretibial oedema, skin induration, discoloration, venous ectasia, redness, and pain during compression) received a score ranging from 0 to 3. We defined post-thrombotic syndrome as severe in the case of a score higher than 14 and as mild in the case of a score of 5-14, on two consecutive examinations. We considered veins as recanalised if they measured less than 2.0 mm in diameter in a single examination or less than 3.0 mm in two consecutive examinations at least three months apart.

Symptomatic recurrent thrombosis in the same arm was diagnosed in case of a (new) intraluminal defect on venography, while symptomatic recurrences in other limbs were diagnosed in case the vein could not be compressed on ultrasonography.1 5

We used Kaplan-Meier estimates to assess the risk of recurrent thromboembolism and post-thrombotic syndrome. We used stepwise Cox regression models to calculate hazard ratios for these outcomes in relation to age, sex, extension of thrombosis (single spot versus axillary or subclavian involvement), modality of clinical presentation (idiopathic versus secondary), thrombophilic status, acquired risk factors of thrombosis, and persistent venous obstruction. All patients gave written informed consent.

Two patients were lost to follow up after two and three years, respectively, and 11 died because of cancer progression, pulmonary embolism, and congestive heart failure.1 Median follow up was 48.3 months.

Three patients developed a recurrent thromboembolism (recurrence in the same arm in two, and a thrombosis in the leg in one). The cumulative incidence of recurrent thromboembolism after one, two, and five years was 2.0% (95% confidence interval 0.0 to 5.9), 4.2% (0.0 to 9.9), and 7.7% (0.0 to 16.5), respectively. Thirteen patients developed post-thrombotic syndrome, one severely so. Ten cases occurred within six months, two after one year, and one after two years. The cumulative incidence of post-thrombotic syndrome was 20.8% (9.3 to 32.3) at six months, 25.1% (12.8 to 37.4) at one year, and 27.3% (14.6 to 40.0) at two years. It remained stable afterwards. The incidence of these outcomes in patients with and without vein catheter is shown in table A on bmj.com.

Residual thrombosis was related to the incidence of post-thrombotic syndrome (hazard ratio 4.0, 1.1 to 15.0). Of other potential risk factors, only thrombosis affecting the axillary and subclavian veins was related, albeit not significantly, to the development of post-thrombotic syndrome (hazard ratio 2.9, 0.8 to 10.7).

Comment

Symptomatic deep vein thrombosis of the arm carries a low risk of recurrent thromboembolism. Post-thrombotic sequelae occur in almost one fourth of patients within the first two years and are related to residual thrombosis and, to a lesser degree, to the extent of the initial thrombosis. The rates of recurrent thromboembolism and post-thrombotic syndrome are lower than those observed in cohorts of patients with venous thrombosis of the leg.4 Whether the incidence of long term sequelae might be further reduced by physical devices or other methods is worth investigating.

Footnotes

  • Embedded Image An additional table showing outcomes in patients with and without vein catheters is on bmj.com

    This article was posted on bmj.com on 15 July 2004 http://bmj.com/cgi/doi/10.1136/bmj.38167.684444.3A

  • Contributors PP, AWAL, AG, and EB conceived and designed the study. PP, AWLA, MHP, and EB drafted the article. MHP and AM offered their statistical expertise for analysing and interpreting data. PP, SV, PB, DS, AP, and PS provided study patients and collected data by following them prospectively over years. AG, AP, AM, and PS critically reviewed the article for important intellectual content. All authors approved the final version of the article. PP is guarantor.

  • Funding None.

  • Competing interests None declared.

  • Ethical approval Institutional Review Board of Padua University.

References

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
View Abstract